India Can Be Biologics Hub with Right Execution: Wockhardt Chairman

• Wockhardt Chairman Habil F Khorakiwala states India can become a biologics hub with proper execution, despite current weaknesses.
• Biologics are crucial for future drug discovery; India needs capacity building in this segment for its pharmaceutical ambitions.
• Union Budget 2026–27's "Biopharma SHAKTI" scheme allocates ₹10,000 crore over five years to transform India into a global biopharma manufacturing hub.
• Khorakiwala emphasizes that money alone isn't enough; success depends on a new execution model, not legacy approaches.
• Indian generic drugmakers supply nearly 40% of US prescriptions, making them critical to the US healthcare system due to cost competitiveness.